Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody
Glucocorticoid (GC) hormone has been commonly used to treat systemic inflammation and immune disorders. However, the side effects associated with long-term use of high-dose GC hormone limit its clinical application seriously. GC hormone that can specifically target the lung might decrease the effect...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , |
|---|---|
| Format: | Livre |
| Publié: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
| Sujets: | |
| Accès en ligne: | Connect to this object online. |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_3ff7c95d3fd84b3cb63d0ffc046af6f2 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Dong Weng |e author |
| 700 | 1 | 0 | |a Zhao-Fang Yin |e author |
| 700 | 1 | 0 | |a Shan-Shan Chen |e author |
| 700 | 1 | 0 | |a Xian He |e author |
| 700 | 1 | 0 | |a Nan Li |e author |
| 700 | 1 | 0 | |a Tao Chen |e author |
| 700 | 1 | 0 | |a Hui Qiu |e author |
| 700 | 1 | 0 | |a Meng-Meng Zhao |e author |
| 700 | 1 | 0 | |a Qin Wu |e author |
| 700 | 1 | 0 | |a Nian-Yu Zhou |e author |
| 700 | 1 | 0 | |a Li-Qin Lu |e author |
| 700 | 1 | 0 | |a Dan-Li Tang |e author |
| 700 | 1 | 0 | |a Jia-Cui Song |e author |
| 700 | 1 | 0 | |a Hui-Ping Li |e author |
| 245 | 0 | 0 | |a Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody |
| 260 | |b Taylor & Francis Group, |c 2021-01-01T00:00:00Z. | ||
| 500 | |a 1071-7544 | ||
| 500 | |a 1521-0464 | ||
| 500 | |a 10.1080/10717544.2021.1921073 | ||
| 520 | |a Glucocorticoid (GC) hormone has been commonly used to treat systemic inflammation and immune disorders. However, the side effects associated with long-term use of high-dose GC hormone limit its clinical application seriously. GC hormone that can specifically target the lung might decrease the effective dosage and thus reduce GC-associated side effects. In this study, we successfully prepared human lung-targeting liposomal methylprednisolone crosslinked with nanobody (MPS-NSSLs-SPANb). Our findings indicate that MPS-NSSLs-SPANb may reduce the effective therapeutic dosage of MPS, achieve better efficacy, and reduce GC-associated side effects. In addition, MPS-NSSLs-SPANb showed higher efficacy and lower toxicity than conventional MPS. | ||
| 546 | |a EN | ||
| 690 | |a acute exacerbation of idiopathic pulmonary fibrosis (ae-ipf) | ||
| 690 | |a humanized surfactant protein-a (hsp-a) | ||
| 690 | |a humanized surfactant protein-a nanobody (spanb) | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Drug Delivery, Vol 28, Iss 1, Pp 1419-1431 (2021) | |
| 787 | 0 | |n http://dx.doi.org/10.1080/10717544.2021.1921073 | |
| 787 | 0 | |n https://doaj.org/toc/1071-7544 | |
| 787 | 0 | |n https://doaj.org/toc/1521-0464 | |
| 856 | 4 | 1 | |u https://doaj.org/article/3ff7c95d3fd84b3cb63d0ffc046af6f2 |z Connect to this object online. |